- Tigem Research Highlights
-
Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin.
-
Light-responsive microRNA miR-211 targets Ezrin to modulate lysosomal biogenesis and retinal cell clearance
-
Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel
-
The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease
-
AAV-miR-204 Protects from Retinal Degeneration by Attenuation of Microglia Activation and Photoreceptor Cell Death.
-
TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKβ/VPS34 pathway.
- Applications for our new Phd Program are now open
-
Applications for the new PhD Program in Genomic and Experimental Medicine of the Scuola Superiore Meridionale are now open. Detailed information about the application process and the direct link to apply may be found visiting this page
- Our Vision
-
TIGEM (Telethon Institute of Genetics and Medicine) is an international research institute dedicated to the discovery of the mechanisms underlying rare genetic diseases and the development of innovative therapies. Learn more >>
- Upcoming Seminars and Events
-
NOTICE:
Due to the pandemic caused by Covid19, all TIGEM seminars have been postponed.TIGEM will stay open but the activities have been reduced: according to ISS guidelines (https://www.iss.it/coronavirus), we implemented very strict procedures in order to guarantee the safety of all personnel.
- Institutional Partnership
-
Tigem can count on an Institutional Partnership with the Department of Translational Medicine of the Federico II University of Naples
